The digoxin-amiodarone interaction

Cardiovascular Drugs and Therapy
K RobinsonD W Holt

Abstract

To assess the cause of the digoxin-amiodarone interaction, the systemic availability and renal excretion of digoxin were examined in 10 patients. Patients were studied before and after 1 week and 6 weeks of concurrent amiodarone therapy, and four were also studied after 4-8 months. Mean (+/- SD) peak plasma digoxin concentration rose from 1.55 +/- 0.6 microgram /1 prior to amiodarone therapy to 2.85 +/- 1.3 micrograms/1 after 1 week of combined therapy (p less than 0.01). Mean AUC also rose from 7.2 +/- 2.1 micrograms/1.h to 12.1 +/- 6.4 micrograms/1.h (p less than 0.01) during this period. Mean peak plasma digoxin concentration and AUC remained elevated after 6 weeks and, in the patients studied, at 4-8 months. Mean urinary digoxin clearance remained unchanged. Plasma amiodarone and desethylamiodarone concentrations were consistent with the prescribed doses. This study confirmed previous findings of raised plasma digoxin concentrations following the addition of amiodarone. It has also shown that this interaction is sustained for at least several months. The cause has not been fully elucidated but does not appear to be due to a change in the renal clearance of digoxin.

References

Mar 1, 1986·Journal of Cardiovascular Pharmacology·N VenkateshR Kannan
Jan 1, 1985·Journal of the American College of Cardiology·P E FensterC D Hanson
Oct 1, 1983·American Heart Journal·F I Marcus
Apr 21, 1984·Lancet·P Douste-BlazyP Bernadet
Mar 1, 1984·The Journal of Pediatrics·G KorenS M MacLeod
Jan 24, 1981·British Medical Journal·J O MoyseyD A Chamberlain
Dec 1, 1981·British Journal of Clinical Pharmacology·G T Tucker

❮ Previous
Next ❯

Citations

Apr 27, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Harma EllensCaroline A Lee
Jun 13, 2008·Biopharmaceutics & Drug Disposition·Leos FuksaStanislav Micuda
Jun 4, 1992·The American Journal of Cardiology·R P Lewis
Sep 4, 1998·The American Journal of Medicine·P E Marik, L Fromm
May 15, 1990·The American Journal of Cardiology·P E NolanF I Marcus
Apr 9, 2013·Journal of the American College of Cardiology·Jeffrey D WesslerRobert P Giugliano
Dec 29, 2016·The AAPS Journal·Kaitlyn V Ledwitch, Arthur G Roberts
Sep 17, 2009·Human & Experimental Toxicology·B M KirraneR S Hoffman
Apr 20, 2000·The Annals of Pharmacotherapy·T MiuraY Suzuki
Oct 14, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Manoj S ChineyAhmed Hamed Salem
Jan 25, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Tsuyoshi MikkaichiTakashi Izumi
Mar 14, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David HamiltonAnthony Hilliard
Apr 24, 2014·Molecular Pharmaceutics·Elnaz GozalpourJan B Koenderink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.